Skip to content

Accounts Payable at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.23B+5.8%
Pfizer logo
PfizerPFE
$4.51B-14.0%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$4.73M-17.6%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$5.73M+353%
Nuvation Bio logo
Nuvation BioNUVB
$22.44M+113%
Immunome logo
ImmunomeIMNM
$5.53M-39.4%

Other financials

Income statement

See full
Operating income-$6.3M-12.4%
Net income-$6.1M-13.5%
EPS (diluted)-$0.26+3.7%

Balance sheet

See full
Cash & equivalents$25.1M-15.9%
Total equity$14.2M-32.1%
Total assets$25.4M-15.8%

Cash flow

See full
Operating cash flow-$6.5M-56.0%

Valuation

See full
Market cap$739.27M+335%

Returns & leverage

See full
Return on equity-154.4%+79.4pp
Current ratio2.3×-1.0×

Where this comes from

Reported directly by Nuvectis Pharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.

The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvectis Pharma, Inc.'s accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvectis Pharma, Inc.'s accounts payable?
Nuvectis Pharma, Inc. (NVCT) reported accounts payable of $4.7M in Q1 2026.
How has Nuvectis Pharma, Inc.'s accounts payable changed year-over-year?
Nuvectis Pharma, Inc.'s accounts payable increased by 56.9% year-over-year, from $2.99M to $4.7M.
What is the long-term trend for Nuvectis Pharma, Inc.'s accounts payable?
Over 4 years (2021 to 2025), Nuvectis Pharma, Inc.'s accounts payable has grown at a 56.1% compound annual growth rate (CAGR), from $1.06M to $6.27M.
What does accounts payable mean?
Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.